ENTRY       D09587                      Drug
NAME        Brentuximab vedotin (USAN/INN);
            Brentuximab vedotin (genetical recombination) (JAN);
            Adcetris (TN)
PRODUCT     ADCETRIS (SEAGEN)
FORMULA     C6476H9930N1690O2030S40. (C68H105N11O15)n
SEQUENCE
  TYPE      Peptide
REMARK      Therapeutic category: 4291
            ATC code: L01FX05
            Product: D09587<JP/US>
EFFICACY    Antineoplastic, Tubulin polymerization inhibitor, Anti-CD30 antibody
  DISEASE   Hodgkin lymphoma [DS:H00007]
            Anaplastic large cell lymphoma [DS:H01601]
            Peripheral T-cell lymphoma (CD30 expressing) [DS:H01892]
            Mycosis fungoides (CD30 expressing) [DS:H01463]
  TYPE      Antibody-drug conjugate
COMMENT     See Vedotin [DR:D09691]
TARGET      TNFRSF8 (CD30) [HSA:943] [KO:K05145]
            TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  PATHWAY   hsa04060(943)  Cytokine-cytokine receptor interaction
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX05 Brentuximab vedotin
                  D09587  Brentuximab vedotin (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Brentuximab Vedotin
                D09587  Brentuximab vedotin (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09587  Brentuximab vedotin (USAN/INN); Brentuximab vedotin (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Tumor necrosis factor receptors
                TNFRSF8 (CD30)
                 D09587  Brentuximab vedotin (USAN/INN) &lt;JP/US&gt;
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                TUBB
                 D09587  Brentuximab vedotin (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09587
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09587
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09587
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09587
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09587
DBLINKS     CAS: 914088-09-8
            PubChem: 124490327
///
